A huge week for news, especially on the cardiovascular front:
Prasugrel, the Lilly/Daiichi-Sankyo blood thinner, was the biggest headline grabber. This potential blockbuster came in with mixed results – good efficacy, but troubling side effects with some patients. Meanwhile, a bit further back in the pipeline, Schering-Plough‘s experimental anti-clotting med continues to look very promising.
Speaking of Schering and blood clots, it appears that smaller doses of Integrilin are just as effective as the more traditional (higher) dosing.
Bayer launches a huge study for its promising blood clot drug rivaroxaban.
Why did Pfizer‘s torcetrapib fail? Some reasons may be surfacing.
Court case: Red Cross 1, J&J 0. But this ain’t over yet…
Cephalon: Loss posted, and Corporate Integrity Agreement signed.
BMS‘s oncology drug Sprycel – new labeling for CML.
J&J/Schering-Plough experimental arthritis drug meets goals in study.
JUST IN: Merck to pay huge amount to settle bulk of Vioxx claims?